Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877547 | 1.00 | CYP3A4 (0.51) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL6876142 | 0.96 | CYP3A4 (0.51) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL6876493 | 0.96 | CYP3A4 (0.51) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL6878699 | 0.94 | CYP3A4 (0.52) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL10060865 | 0.94 | CYP3A4 (0.52) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL6875218 | 0.94 | ADRB3 (0.57) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL10060800 | 0.94 | ADRB3 (0.50) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL12629745 | 0.94 | ADRB3 (0.50) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL10060798 | 0.94 | ADRB3 (0.57) | CYP3A4ADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL16508661 | 0.92 | ADRB3 (0.51) | CYP3A4ADRB3ADRA2BADRA2CCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077737-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20110294778-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2011063502-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294778-A1 | HEPATITIS C INHIBITOR COMPOUNDS | ABCC1, CTRC, HAVCR2 | CYP3A4 106/4885ADRB3 3371/4885ADRA2B 2756/4885 |
| US-20120077737-A1 | HEPATITIS C INHIBITOR COMPOUNDS | CTSC, HCCS, CTSZ | CYP3A4 793/4885ADRB3 4693/4885ADRA2B 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.